Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Carsten B Thomsen"'
Autor:
Thomas Mohr, J Asger Petersen, Christian Østergaard, Morten Steensen, Anne Øberg Lauritsen, Paul Christian Fjeldborg, Lars Hein, Jesper Kjaer, Jesper Løken, Sine Hougaard, Pernille L. Petersen, Peter Søe-Jensen, Søren Hestad, Lasse H. Andersen, Mads H. Andersen, Klaus J. Thornberg, Katrin Thormar, Teit Mantoni, Peder Carl, Morten H. Bestle, Bettina Lundgren, Jens-Ulrik Stæhr Jensen, Bonnie Bømler, Charlotte Dahl Rossau, Hamid Tousi, Carsten B Thomsen, Kim M Larsen, Jesper Grarup, Jens D Lundgren
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 8, Iss 1, p 91 (2008)
Jensen, J-U, Lundgren, B, Hein, L, Mohr, T, Petersen, P L, Andersen, L H, Lauritsen, A O, Hougaard, S, Mantoni, T, Bømler, B, Thornberg, K J, Thormar, K, Løken, J, Steensen, M, Carl, P, Petersen, J A, Tousi, H, Søe-Jensen, P, Bestle, M, Hestad, S, Andersen, M H, Fjeldborg, P, Larsen, K M, Rossau, C D, Thomsen, C B, Ostergaard, C, Kjaer, J, Grarup, J & Lundgren, J D 2008, ' The Procalcitonin And Survival Study (PASS)-a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients ', B M C Infectious Diseases, vol. 8, pp. 91 . https://doi.org/10.1186/1471-2334-8-91
BMC Infectious Diseases, Vol 8, Iss 1, p 91 (2008)
Jensen, J-U, Lundgren, B, Hein, L, Mohr, T, Petersen, P L, Andersen, L H, Lauritsen, A O, Hougaard, S, Mantoni, T, Bømler, B, Thornberg, K J, Thormar, K, Løken, J, Steensen, M, Carl, P, Petersen, J A, Tousi, H, Søe-Jensen, P, Bestle, M, Hestad, S, Andersen, M H, Fjeldborg, P, Larsen, K M, Rossau, C D, Thomsen, C B, Ostergaard, C, Kjaer, J, Grarup, J & Lundgren, J D 2008, ' The Procalcitonin And Survival Study (PASS)-a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients ', B M C Infectious Diseases, vol. 8, pp. 91 . https://doi.org/10.1186/1471-2334-8-91
Background Sepsis and complications to sepsis are major causes of mortality in critically ill patients. Rapid treatment of sepsis is of crucial importance for survival of patients. The infectious status of the critically ill patient is often difficul